[HTML][HTML] Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 …
G Yang, H Xu, Y Yang, S Zhang, F Xu, X Hao, J Li… - BMC medicine, 2022 - Springer
Background Although targeted agents have been gradually applied in the treatment of
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study …
G Yang, H Xu, Y Yang, S Zhang, F Xu, X Hao… - BMC …, 2022 - search.ebscohost.com
Abstract < bold> Background: </bold> Although targeted agents have been
gradually applied in the treatment of HER2-mutated non-small cell lung cancer (NSCLC) in …
gradually applied in the treatment of HER2-mutated non-small cell lung cancer (NSCLC) in …
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study …
G Yang, H Xu, Y Yang, S Zhang, F Xu, X Hao… - BMC …, 2022 - search.proquest.com
Background Although targeted agents have been gradually applied in the treatment of
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
[HTML][HTML] Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 …
G Yang, H Xu, Y Yang, S Zhang, F Xu, X Hao, J Li… - BMC …, 2022 - ncbi.nlm.nih.gov
Background Although targeted agents have been gradually applied in the treatment of
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study …
G Yang, H Xu, Y Yang, S Zhang, F Xu, X Hao, J Li… - BMC Medicine, 2022 - europepmc.org
Background Although targeted agents have been gradually applied in the treatment of
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study …
G Yang, H Xu, Y Yang, S Zhang, F Xu… - BMC …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Although targeted agents have been gradually applied in the treatment of
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
[HTML][HTML] Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 …
G Yang, H Xu, Y Yang, S Zhang, F Xu… - BMC …, 2022 - bmcmedicine.biomedcentral.com
Although targeted agents have been gradually applied in the treatment of HER2-mutated
non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic demands are far …
non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic demands are far …
[PDF][PDF] Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study …
G Yang, H Xu, Y Yang, S Zhang, F Xu, X Hao, J Li… - 2022 - bmcmedicine.biomedcentral.com
Background: Although targeted agents have been gradually applied in the treatment of
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …
HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients' therapeutic …